Earnings Preview: Johnson & Johnson EPS, Revenue Expected to Rise from Previous Quarter

It's time to gear up for Johnson & Johnson JNJ earnings! Keep your head in the game: The company releases its next round of earnings this Tuesday, July 19, 2011.

Want to get all the facts ahead of this Tuesday's announcement? We thought so. Here's an advanced look at Johnson & Johnson's second quarter earnings report.

Let's Do the Numbers:

Analysts are looking ahead to a positive EPS reading of $1.24 per share and revenues of $16.22 billion. We'll know on Tuesday whether Johnson & Johnson has managed the estimated 97% increase in EPS and 106% rise in revenues on a year-over-year basis.

Here's how the company's reported EPS has stacked up against analyst estimates in the past:

Quarter	Q1	Q4	Q3	Q2
EPS Estimate	$1.25	$1.03	$1.15	$1.21
EPS Actual	$1.35	$1.03	$1.23	$1.21

Stock Performance:

Shares of Johnson & Johnson were trading at $67.63 as of July 13, 2011. Since January 1st, shares of Johnson & Johnson have given investors a return of 11.3%. For a full 12 months, the return has risen by 8.7%. Given that these returns are generally positive, long-term shareholders are probably satisfied going into this earnings release.

• Long-term shareholders are already enjoying 12-month gains prior to the announcement

Average Stock Rating:

The average rating by analysts for Johnson & Johnson is a Moderate Buy.

Competitors:

Wondering how some of the other healthcare companies are doing? Here are a few of Johnson & Johnson's peers in that sector.

• Abbott Laboratories ABT: Hold with a $0.91 recent quarter EPS
• Boston Scientific BSX: Hold with a $0.14 recent quarter EPS

Johnson & Johnson is in the large cap pharmaceutical industry, which has experienced price/earnings growth of 3%.

Finally, a description of the main business areas of the company, in case you need a little refresher: Johnson & Johnson is a holding company involved in the research and development, manufacture and sale of a range of health care products.

Take Action:

Now that you're fully prepared, get ready to take quick action if the company reports any numbers significantly different from those listed above. Also, check back in with us after the announcement for a full recap and what-to-do-next guide.

• To see up-to-date news on Johnson & Johnson, click here
• To see other trading ideas, click here
• To see other company earnings recaps, click here